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 Abstract 
ABSTRACT 
 
Viral-mediated gene therapy holds great promise for the treatment of severe 
inherited retinal diseases, such as Retintitis Pigmentosa (RP), which is caused 
by mutations in genes preferentially expressed in photoreceptor cells. The 
availability of vectors derived from the small adeno-associated virus (AAV) 
which efficiently and stably transduce the retina of animal models after 
intraocular administration strongly support the possibility to develop novel 
strategies for the treatment of such severe retinal degenerations otherwise 
incurable thus far.  
The main goals of my PhD project were: 
- generate artificial transcription repressors (ZFPs) targeted to the human 
rhodopsin promoter to silence at the transcriptional level the rhodopsin 
gene; 
- assess the efficacy of the treatment and the impact on the disease 
progression in the RP mouse model. 
Retinitis pigmentosa is by far the most studied inherited retinal disease. It is 
clinically and genetically heterogeneous recognizing autosomal recessive 
(arRP), autosomal dominant (adRP), X-linked, and digenic patterns of 
inheritance. More than 30 diseases genes have been identified so far and 12 of 
these have been associated with (adRP), representing between 15% and 35% 
of all cases. Despite recent success of the gene-based complementation 
approach for genetic recessive traits, the development of therapeutic strategies 
for gain-of-function mutations poses great challenges. General therapeutic 
principles to correct these genetic defects mostly rely on post-transcriptional 
gene regulation (RNA silencing). Engineered zinc finger protein (ZFP)-based-
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repression of transcription may represent a novel and alternative mutation 
independent therapeutic approach for treating gain-of-function mutations, but 
proof-of-concept of this use is still lacking. In my PhD project we used a novel 
strategy to treat adRP based on zinc-finger-based artificial transcription factors 
(ZF-ATFs). These molecules can be engineered to silence genes carrying gain-
of-function mutations that cause toxic effects into the cell where they are 
expressed. We generated ten artificial transcriptional repressors targeted to the 
human Rhodopsin which is the gene most commonly associated with adRP 
(20–30% of cases) with more than 150 mutations identified throughout its 
sequence, representing the most commonly mutated gene in RP. 
We characterized in vitro the ability of artificial transcriptional repressors to bind 
specifically the human rhodopsin promoter in order to exert a specific 
transcriptional control and we selected two out of ten functional zinc-finger-
based repressors of rhodopsin. One of this was selected as the most efficient 
and was enclosed in an AAV2/8 for in vivo experiments. We demonstrated that 
the selected artificial zinc-finger-based repressors (ZFRs) resulted in a robust 
transcriptional repression of hRHO impacting disease progression in a mouse 
model of adRP over-expressing the P347S mutation. 
The data obtained support the use of ZFP-mediated silencing as a potentially 
relevant therapeutic strategy to treat gain of function mutations. 
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INTRODUCTION 
 
1. THE RETINA AND INHERITED PHOTORECEPTOR DISEASES 
 
1.1 Structure of the eye and the retina 
The eye is perhaps the most important sensory organ for humans and it is the 
first component of the visual system which allows assimilating information from 
the environment. This ability is called “Visual Perception” and it is by far the 
most complex sensory system. This is due to the fact that vision must handle 
demands such as the 
transduction of light stimuli to 
neural impulses, the binocular 
and more distant depth 
perception and the colour 
discrimination. 
The structure of the human eye 
(Fig. 1) can be divided into three 
main layers or tunics whose 
names reflect their basic 
functions: the fibrous, the vascular, and the nervous tunics. The fibrous tunic, 
also known as the tunica fibrosa oculi, is the outer layer of the eyeball 
consisting of the cornea and sclera. It consists of dense connective tissue filled 
with the collagen to both protect the inner components of the eye and maintain 
its shape. The vascular tunic, also known as the tunica vasculosa oculi, is the 
middle vascularized layer, which includes the iris, ciliary body, and choroids. 
The iris sits between the anterior chamber which contains the aqueous humour 
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essential for nourishing the lens and the cornea, and the posterior chamber 
filled with the vitreous humour. This substance is jelly-like and, besides helping 
the eye to keep its shape, it transmits the light to the back of the eye. The lens 
is a clear, flexible structure responsible for sharpening of the image at the retina 
and it is connected to the ciliary body (which contains the ciliary muscles). The 
choroid contains blood vessels that supply the retinal cells with necessary 
oxygen and remove the waste products of respiration. The nervous tunic, also 
known as the tunica nervosa oculi, is the inner sensory structure, which 
includes the retina. 
ggggg  
Retina is a light sensitive tissue lining the inner surface of the eye (Fig. 2). It is 
a highly organized array of neurons, which serve as transducer for the 
conversion of the light into neuronal signals which eventually reach the brain. 
Due to the complexity of this process, retinal cells give rise to a variety of 
neuronal cell types, which conduct and facilitate the entire cascade of events. 
Retina is composed of seven classes of cells structured in layers: photoreceptor 
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cells (rods and cones), bipolar cells, horizontal cells, amacrine cells, Müller glia 
cells and retinal ganglion cells (Fig. 2). 
The most outer layer is the retinal pigment epithelium (RPE), which is situated 
between the choroid and the photoreceptors. RPE nourishes the retina and is 
involved in the phagocytosis of the outer segment of photoreceptor cells and is 
also involved in the chromophore regeneration (see section 1.3). The second 
layer, the photoreceptor layer, comprises the outer and the inner segments of 
photoreceptors (rods and cones), while the photoreceptors cell bodies form the 
outer nuclear layer (ONL). At the synaptic terminals of photoreceptors, in a 
region called the outer plexiform layer (OPL) light induced signals are 
transferred from rods and cones to bipolar and horizontal cells which together 
with Müller glia and amacrine cells form the inner nuclear layer (INL). Horizontal 
cells provide lateral interaction in the OPL and aid in signal processing. One 
type of rod bipolar cells and at least 10 different types of cone bipolar cells 
transfer light-induced signals to the inner plexiform layer (IPL), which comprises 
dendrites of amacrine cells and ganglion cells. Amacrine cells are inhibitory 
interneurons; there are about 40 different subtypes. Müller cells are the main 
glial cells of the retina. They form architectural support structures stretching 
radially across the thickness of the retina and set the limits of the retina at the 
outer and inner limiting membranes, respectively. Dendrites of amacrine cells, 
bipolar and ganglion cells form the inner plexiform layer (IPL). The ganglion cell 
layer (GCL) forms the innermost retinal layer. Ganglion cell dendrites collect the 
signals of bipolar and amacrine cells and transmit these signals through their 
axons, which form the optic nerve, to the visual centres of the brain1. 
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1.2 The photoreceptor cells 
Perception of light initiates in the highly specialized retinal cells called 
photoreceptors (Fig. 3). Photoreceptors are highly polarized retinal neurons 
with the unique property of transforming physical signals (photons of light) first 
into biochemical messages and then 
into electrical message “perceived” by 
specialized brain structures (visual 
cortex). Photoreceptors contain four 
distinct compartments: the outer 
segment (OS), a thin cilium, which 
connects the outer to the inner 
segment (IS), a cell body containing 
the nucleus and the cytoplasm and a 
short axon connecting the 
photoreceptor cell to interneurons (Fig. 
3). The OS is the compartment in which 
the conversion of light energy into electrical signals (phototransduction 
cascade) occurs. It consists of an array of flat membranous disks that arise 
during development as a series of invagionations of the cell’s plasma 
membrane. These discs disintegrate near the apical surface of the cells and the 
cellular debris are removed through phagocytosis by the adjacent RPE2 
following a diurnal rhythm. The old discs are gradually replaced by newly 
formed ones that migrate to the base of the OS3. The IS contains most of the 
photoreceptor metabolic machinery, including the ER, the Golgi apparatus, and 
the mitochondria. Cellular components and metabolites are exchanged and/or 
transported between the IS and OS through the narrow connecting cilium. 
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There are two types of photoreceptor cells in the human retina: rods which 
mediate dim-light vision and cones which function in bright light. Rods represent 
95% of photoreceptor cells in the human retina and are responsible for sensing 
contrast, brightness and motion. They contain a photopigment called rhodopsin 
(RHO, max absorbance 500 nm) which is capable of trapping photons. The 
cones perceive fine resolution, spatial resolution, and colour vision and they 
contain three different colour pigments, blue-sensitive pigment (445 nm), green-
sensitive pigment (535 nm) and red-sensitive pigment (570 nm) sensitive to 
different colours: blue, green and red respectively1. In humans, cone density is 
maximal in the fovea, which contains about 10% of the cones of the retina; their 
density decreases drastically across the macula, beyond the borders of which 
density is relatively constant but asymmetric, with higher densities on the nasal 
side of the retina. Rods are also distributed unevenly across the retina: there 
are no rod photoreceptors within of the fovea. Beyond this rod-free zone, they 
increase rapidly to reach a peak along an elliptical ring at the eccentricity of the 
optic disc. In rodents, fovea is not present and photoreceptors are constantly 
distributed through the retina. 
 
1.3 The phototransduction cascade 
Transduction of absorbed light into electrical signal that is eventually perceived 
as sight takes place within photoreceptor cells via a complex molecular process 
called phototransduction4. Rod phototransduction has been more 
comprehensively studied than cones one. It takes place in the rod OS discs 
with the absorption of light by rhodopsin which is a photopigment that counts for 
80% of total amount of rod outer segment proteins. It is composed of a 
backbone, termed rod-specific opsin, a seven transmembrane G-protein-
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coupled receptor, bound to the light-sensitive chromophore 11-cis-retinal 
(11cRAL) a derivative of vitamin A5. The phototransduction cascade initiates 
when the visual pigment, rhodopsin, absorbs a photon (hv; Fig. 4). This induces 
a conformational change of the chromophore to all-trans, which still has the 
same chemical structure as the cis but a different physical form. Because the 
all-trans-retinal (atRAL) no longer fits with the rhodopsin, it begins to pull away 
from it until there is a complete split (within seconds). This in turn induces 
conformational changes in the rhodopsin which is activated (R*). This 
intermediate molecule (metarhodopsin II) interacts with the next member of the 
cascade, a G-protein called Transducin (G) which is an heterotrimeric protein 
(). This interaction induces the  subunit of the transducin to exchange a 
bound guanosine diphosphate (GDP) moiety to guanosine triphosphate (GTP). 
The activated GTP-bounded  subunit (G*) detaches from the  and  
subunits of the transducin and associated with the next member of the cascade, 
the phosphodiesterase 6 (PDE6) which is a multisubunit complex, composed of 
two tightly bound catalytic subunits,  (99kDa, PDE) and  (98kDa, PDE) in 
addition to two identical inhibitory  subunits of 11kDa. The enzyme is anchored 
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to the rim membrane by an isoprenylic group at the C-terminus of the  and  
subunits. The G* subunit interacts directly with the inhibitory  subunit of the 
PDE6. An increase in the activity of the cGMP phosphodiesterase at this stage 
induces a fall in the concentration of cGMP in the cytoplasm5 which leads to the 
closure of cGMP-gated cation (Na+ and Ca++) channels on the plasma 
membrane of the rod’s OSs with a consequent decline in calcium concentration 
within the cell. This causes a graded hyperpolarization of the plasma 
membrane which is conveyed, as in all neuronal cells, to the synaptic region of 
the rod where it decreases the amount of neurotransmitter (glutamate) release. 
This initial signal is transmitted via second-order retinal neurons to the optic 
nerve and to the brain. The decline in calcium concentration mediates the 
recovery of the photoreceptor cell after a bleach of light. This is as important for 
maintaining sensitivity in vision as the cell’s ability to respond to a single 
photon. Deactivation of rhodopsin starts with phosphorylation by rhodopsin 
kinase (RHOK) and is followed by the capture of rhodopsin by the protein 
arrestin6. The arrestin-binding prevents further activation of transducin and 
releases the all-trans-retinal from rhodopsin. The concentration of cGMP within 
the cell is restored by the increased synthesis of cGMP by a retinal guanylate 
cyclase (GC). These pathways are triggered by the decline in the intracellular 
calcium concentration and mediated by a family of calcium-binding proteins, 
including recoverin and guanylyl cyclise activating protein (GCAP). The 
calcium-bound recoverin inhibits the activity of rhodopsin kinase7. Sustained 
phototransduction depends on replenishing the 11-cis-retinal lost as a result of 
light activation of the visual pigments in a pathway which takes place between 
the photoreceptor cells and the RPE in a process called visual cycle8. 
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1.4 The visual cycle pathway 
Absorption of a photon of light by rhodopsin causes isomerisation of the 
chromophore from 11-cis-retinal to all-trans-retinal. In order to restore light 
sensitivity of rhodopsin all-trans-retinal must be converted back to 11-cis-retinal 
through a multistep pathway called visual cycle (Fig. 5). Visual cycle initiates in   
f
 
the photoreceptor cells, precisely in the inner surface of the rod disks 
membrane, with the release of all-trans-retinal which is subsequently 
transferred to cytoplasmic surface of the disks by retina-specific ATP-binding 
cassette transporter (ABCA4)9; 10. In the photoreceptor cytoplasm, all-trans-
retinal is reduced by an all-trans retinol dehydrogenase (atRDH) and the 
resulting all-trans retinol (vitamin A) is transported across the subretinal space 
to the RPE. Within the RPE, all-trans-retinol is bound to cellular retinal binding 
protein (CRBP)11 and immediately esterified to all-trans-retinyl esters (atRE) by 
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lecithin retinol acyltransferase (LRAT)12. atRE is isomerized to 11-cis-retinol by 
isomerohydrolase (IMH) in conjunction with RPE65 protein. The resulting 11-
cis-retinol (11cROL) is oxidized by the retinol dehydrogenase (11cisRDH) to the 
final product 11-cis retinal13. The 11-cis-retinal exits the RPE, traverses the 
subretinal space, and enters the photoreceptor outer segments where it 
combines with opsin protein to form a new molecule of light-sensitive 
odopsin. rh
 
1.5 Inherited retinal diseases 
The complex retinal structure and signalling network, which includes numerous 
neurotransmitters, neuromodulators, phototransduction proteins, transcription 
factors, etc., lead to a wide range of targets for potential events that may cause 
pathogenic changes in its function. According to some estimates14 the eye is 
the fourth system most commonly affected by genetic diseases in humans. At 
the same time, genetic eye diseases, both monogenic and genetically complex, 
comprise the commonest causes of blindness in children and adults 
worldwide15. Out of different eye diseases, retinal disorders are especially 
important since there are more then 100 diseases that include a form of retinal 
dystrophy, as listed in the online database of human genetic diseases (Online 
Mendelian Inheritance in Man-OMIM). In the industrialized world, the most 
common diseases involving the retina are diabetic retinopathy, glaucoma, and 
age-related macular degeneration (AMD), which together affect several percent 
of the population16. Each of these diseases has both genetic and non-genetic 
components. Contrary to complex diseases, the simple Mendelian retinal 
diseases have an earlier onset and some have a more severe clinical course 
than typically observed for the three more common disorders listed above and, 
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for the most part, they are untreatable. These characteristics, together with the 
possibility of exploiting genetic approaches to understand disease mechanisms, 
have drawn attention on the Mendelian disorders. Retinitis pigmentosa is by far 
the most studied inherited retinal degeneration and it may serve as an example 
f remarkable genetic heterogeneity connected with retinal dystrophies.  
f visual acuity and 
efective colour vision are the prominent early symptoms. 
o
 
1.6 Retinitis Pigmentosa 
Retinitis Pigmentosa (RP) is the term given to a set of inherited retinal 
degeneration with a prevalence of 1:3500 worldwide17; 18 neither preventable 
nor curable19; 20. It is an highly variable disorder, indeed some patients develop 
symptomatic visual loss in childhood whereas others remain asymptomatic until 
mid-adulthood. Many patients fall into a classic pattern of difficulties with dark 
adaptation and night blindness in adolescence and loss of mid-peripheral visual 
field in young adulthood. As the disease advances, they experience a drop of 
far peripheral vision which, develops in tunnel vision and eventually in central 
vision lost, usually by age 60 years20. Visual symptoms indicate the gradual 
loss of the two photoreceptor types: first loss of rods, which mediate achromatic 
vision in starlight or moonlight and are more abundant in the peripheral retina, 
then loss of cones, which are important for colour vision and fine acuity in 
daylight. Most patients are legally blind by age 40 years because of severely 
constricted visual field.  In most form of RP, loss of rod function exceeds 
reduction of cone sensitivity. In other types, rod and cone decline is similar. 
Occasionally, the deficit of cones far exceeds that of rods; in this case the 
disease is termed cone-rod degeneration, and loss o
d
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1.6.1 Diagnosis of RP 
Clinically, RP patients are diagnosed based on three main abnormalities: 
ges of the retina and RPE, abnormal 
electroretinogram (ERG) and attenuation of 
the retinal vasculature and changes to the 
optic nerve head18. In addition, reduction of 
the visual field, colour vision impairment, dark 
adaptation or cataracts, which is showed in 
about 50% of individuals with RP, can be 
observed. Pigmentary changes in the retina 
are evident during the fundus examination 
and remain a common factor in RP diagnosis 
(Fig. 6); they mainly consist in marked 
pigment epithelial thinning, optic disc pallor 
and the classical “bone spicule deposits which result from the release of 
pigment by degenerating cells in the retinal pigment epithelium. The pigment 
granules accumulate in perivascular clusters, known as “bone-spicule 
formations” due to their morphological appearance, in the neural retina. 
Consequently, early in the disease, the pigmented posterior pole of the eye, the 
fundus, develops a granular appearance. This is followed by the development 
of bone-spicule pigmentary deposits overlying the depigmented fundus21. The 
main tool for diagnosis and classification of retinitis pigmentosa is the 
Electroretinogram (ERG) which is an objective measure of retinal function and it 
is useful for accurate diagnosis of disease, for assessment of severity, to follow 
the course of the disease, to provide a visual prognosis and for measurement of 
responses to treatments. In this procedure, retina is either dark adapted 
atrophy and pigmentary chan
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(scotopic ERG) or adapted to a specific level of light (photopic ERG), and then 
stimulated with a brief flash of light. The summed electrical response of the 
retina is recorded extraocularly with a contact lens electrode. A single-flash dim 
blue light elicits a rod response, a brighter single-flash white light elicits a 
combined rod-plus-cone response, and flickering (30Hz) white stimuli generate 
cone-isolated response. With single flashes (0-5 Hz) of white light, an initial a-
wave shows hyperpolarisation of photoreceptors and a subsequent b-wave 
result from depolarisation of cells in the inner nuclear layer. Typically, patients 
with RP have reduced rod and cone response amplitudes and a delay in their 
timing18 (Fig. 7). 
g  g
 
1.6.2 Genetic of Retinitis Pigmentosa (RP) 
Retinitis Pigmentosa is due to many distinct causes and involves diverse 
biological pathways but with overlapping symptoms and similar consequences. 
Most forms of RP are monogenic and can be inherited with classical patterns18; 
22: autosomal dominant (adRP) forms account for 30-40% of total cases, 
autosomal recessive (arRP) forms are the most common variants with a 
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frequency of 50-60% while X-linked (X-lRP)  can be observed in 5-15% of 
affected individuals. However, some unusual patterns as digenic inheritance23 
or maternal (mitochondrial) inheritance24 have also been reported in the 
literature. In most cases, patients with Retinitis Pigmentosa have no associated 
systemic or extraocular abnormalities.  Moreover, there are multisystem 
diseases in which RP is accompanied by involvement of other tissues and 
organs. Examples are Usher’s syndrome (USH), in which Retinitis Pigmentosa 
is associated with hearing impairment and it is the most frequent syndromic 
form (10-20% of total cases)25, or Bardet-Biedl syndrome, where RP is 
associated with obesity, cognitive impairment, polydactyly, hypogenitalism, and 
renal disfunction26. A remarkable feature of Retinitis Pigmentosa is its high 
genetic heterogeneity: so far, more than 50 genes responsible for non-
syndromic forms have been identified that accounts for 60% of total cases20 
(RetNet: http://www.sph.uth.tmc.edu/Retnet/) while about 40% of cases are due 
to genes not yet mapped. Mutations in genes preferentially expressed in 
photoreceptors are the most common cause of RP followed by RPE-specific 
genes. In rare cases RP is caused by mutations in genes expressed in other 
retinal cell types or outside the eye. Despite the genetic heterogeneity of RP, 
photoreceptor cells mainly degenerate by apoptosis27 although the mechanisms 
by which the genetic defect leads to cell death are still unclear28. According to 
the known or presumed function of the encoded proteins, the genes responsible 
for RP so far identified  have been clearly grouped into functional categories as 
schematically depicted in Table 120. Some of these genes encode proteins in 
the rod photoreceptor cascade, the specific biochemical pathway that 
transduces light stimuli and leads to changes in photoreceptor-cell polarisation. 
Recessive null mutations in any of these genes would evidently interfere with 
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rod function and produce night blindness from birth.  Subsequent death of rod 
photoreceptors is probably an outcome of the deranged physiology associated 
with the defective or absent gene product. For example, without functional rod 
cGMP phosphodiesterase, arising with recessive defects in PDE6 or PDE6, 
cGMP concentrations in rod photoreceptor outer segment rise and this in turn 
opens cGMP-gated channels in the plasma membrane. Rods apparently die 
zz       
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from the rush of cation flowing into the cells through these open channels29. 
Another relevant example is given by dominant mutations in rhodopsin gene 
which are probably detrimental to rods because the mutant forms of the protein 
are toxic to rod photoreceptors. The toxic effects are attributable to interference 
with metabolism, perhaps by formation of intracellular protein aggregates, from 
a defect in intracellular transport, or from a fault in the structure of the 
photoreceptor outer segments30. The reason why mutations in genes 
exclusively expressed in rod photoreceptors cause the death of both rod and 
cone cells is not yet clear. The secondary death of cones might be due to 
reliance on neighbouring rods for survival. The discovery of the RdCVF protein, 
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a factor released from rods that promote cone survival, provides a possible 
explanation to this question31. The second most common group of genes 
mutated in RP are involved in visual cycle, in particular in recycling the 
rhodopsin chromophore 11-cis-retinaldehyde18. An example is the gene RPE65 
which is primarily expressed in the RPE and endowed with isomerise activity for 
the rhodopsin ligand 11-cis-rtinal32. Mutations in genes encoding photoreceptor 
structural proteins or transcription factors have also been identified. Moreover, 
some genes for RP are expressed in tissue outside the eye, and others encode 
proteins that are essential for life. For example, non syndromic RP is caused by 
dominant mutations in genes PRPF31, PRPF8 and PRPF3 that encode 
components of the spliceosome, a vital complex that excises introns from RNA 
transcript33. 
 
1.6.3 RP due to rhodopsin mutations 
Mutations in the rhodopsin gene are the most common cause of Retinitis 
Pigmentosa among human patients and account for 20-30% of adRP cases34-37 
(Fig. 8). Rhodopsin is the light-absorbing protein that mediates vision at low 
light levels. Like other visual pigments, it consists of a chromophore  (11-cis-
retinal) covalently bound to an integral membrane protein  (opsin). 
Photoisomerization of  retinal  from 11-cis  to all-trans  induces  a  
conformational  change in the apoprotein, leading  to a conformation that  is 
competent to  activate  the  photoreceptor-specific G-protein  transducin, 
thereby  initiating  the phototransduction cascade. In mammals, rhodopsin 
accumulates to a level of 5x107 molecules/rod outer segment and is 
synthesized throughout life at a rate of 5x106 molecules/rod/day38. Rhodopsin is 
localized to the rods outer segments which contain hundreds of flattened 
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membrane sacs (also called disks) stacked in close apposition and where it 
represents the 80% of total proteins content39. Over 150 mutations in the 
rhodopsin gene leading to autosomal dominant RP (adRP) have been 
characterized so far which can be grouped in two distinct classes of 
biochemical defect. Approximately 85% of the mutant proteins (class II) occurs 
in the N-terminus of the protein and are produced at lower levels than the wild 
zzz  
type, accumulate predominantly in the endoplasmic reticulum, and bind 11-cis-
retinal variably or not at all. This class of proteins appears to be defective in 
folding and/or stability. The remaining 15% of mutant proteins (class I) map 
very close to the C-terminus, a region of the protein for which no function has 
yet been assigned, and resemble the wild type protein, indeed are produced at 
high levels, accumulate in the plasma membrane and efficiently bind to 11-cis-
retinal to form photolabile pigments40; 41. Because these rhodopsin mutations 
were identified in the heterozygous condition in patients with adRP, it seems 
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likely that the mutant proteins interfere with or participate aberrantly in some 
physiological process. A second possibility is that they are physiologically silent 
and that RP results from haploinsufficiency, a scenario that seems unlikely in 
light of the finding that heterozygous carriers of one apparently null mutation in 
the rhodopsin gene do not have RP42. Such mutational heterogeneity 
represents a significant barrier to the development of therapies for adRP 
associated with rhodopsin gene. 
 
1.6.4 Current treatment protocols for RP 
At the moment, no cure is available for RP but some pharmacological 
treatments are recommended by clinicians to slow visual loss. Nutritional or 
neuroprotective treatments that affect secondary biochemical pathways have 
the advantage of being less dependent on the disease-causing mutation and 
could therefore be widely applicable.  
For example, based on a study of the natural course of Retinitis Pigmentosa, 
patients assuming vitamin A, vitamin E, or both were recorded to have slower 
declines in ERG amplitudes than those not taking such supplements43. This 
observation prompted a randomised clinical trial of oral vitamin A and E 
supplements in 601 patients with dominant, recessive and X-linked non-
syndromic Retinitis Pigmentosa and Usher’s syndrome type II. Patients 
assigned high-dose vitamin A showed a significantly slower decline in cone 
ERG amplitudes than did those in the other groups. Based on these results, 
many clinicians recommend that adults with early or middle stages of Retinitis 
Pigmentosa take 15,000 IU of oral vitamin A palmitate every day and avoid high 
dose vitamin E supplements. Toxic effects have not been reported, even if older 
individuals could also be monitored for bone health because a slight increased 
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risk for hip fractures due to osteoporosis has been reported in postmenopausal 
women and men older then 49 years who take vitamin A supplements43. 
Another nutritional treatment assessed for patients with Retinitis Pigmentosa is 
docosahexaenoic acid (DHA), an omega-3 fatty acid found in high 
concentration in oil fish. DHA is apparently important for the photoreceptor 
membrane, since membranes containing rhodopsin and cone-opsin in 
photoreceptor cells have very high dose of this fatty acid. Amounts of DHA in 
red-blood cells are on average lower in patients with RP than in unaffected 
people. Nevertheless, results from two independent studies of oral DHA 
supplements to individuals with Retinitis Pigmentosa did not show clear benefits 
even if people with the highest concentrations of DHA in red-blood cells had the 
slowest rates of retinal degeneration44.  
Further, finding of work done in animals have shown that some neurotrophic 
factors can promote photoreceptor survival45; 46. Results of a human phase I 
study of an intravitreal capsule containing cells that release ciliary neurotrophic 
factor have been reported. Small-molecule drugs are also being assessed as 
possible treatments for RP. For example, in a study of a calcium-channel 
blocker (diltiazem), researchers claimed a beneficial effect in a mouse model of 
RP due to recessive mutations in the -subunit of rod phosphodiesterase. 
However, three subsequent trials of this drug in mice and other animal models 
by independent groups failed to confirm a benefit47; 48. 
Lastly, nanotechnology and biotechnology leading company make great effort 
in order to develop devices to electrically stimulate the retina, optic nerve, or 
visual cortex. The first results obtained are encouraging since the few people 
testing the first version of these devices have reported seeing phosphenes 
(flash of light) in response to direct retinal stimulation49. 
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It’s anyway clear that, increasing the knowledge of the biochemical defects 
associated to RP is essential to develop diverse approaches for the treatment 
of such challenging disease. Nevertheless, these data show that the above-
mentioned approaches cannot be considered a real therapeutic option to halt or 
reverse RP thus far.
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2. GENE THERAPY FOR RETINAL DISEASES 
 
2.1 Gene therapy and the retina 
Gene therapy aims at delivering corrective genetic material to a cell, tissue or 
target organ in order to prevent or cure a disease50. Nucleic acids do not readily 
cross cell membranes; consequently, it is necessary to envelope the genetic 
material in a lipidic-containing complex or incorporate it in a viral vector51; 52. 
The former inserts genetic material directly into the target cells by fusing to the 
host cell membrane. Unfortunately they are not selective for a target cell, have 
low transduction efficiency and mediate short-lived gene expression51; 52. On 
the other hand, viral delivery of therapeutic genes appears much more 
promising since a prolonged transgene expression is obtained with the use of 
particular recombinant viral vectors51. 
The retina represents an ideal target organ for gene therapy approaches for a 
number of reasons: i) it is easy to manipulate and the small size of the eye 
allows the use of low doses of vector; ii) the partial immune privileged 
properties of the eye can limit immune responses toward the transgene and the 
vector; iii) the eye is enclosed and the presence of the blood–retinal-barrier, of 
the RPE and of the intracellular junctions in the inner retina can help avoiding 
unintentional spreading of vectors to neighbouring tissues as well as to the 
general circulation; iv) non invasive in vivo techniques for ocular tissues 
imaging and visual function evaluation are available (Electroretinogram, ERG; 
Optical Coherence Tomography, OCT); v) since ocular diseases develop 
bilaterally and symmetrically, if one eye is treated the other can be used as an 
useful untreated internal control; vi) surgical procedures have been adapted for 
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the transfer of genetic material into the two main ocular compartments 
(Subretinal and intravitreal).  
 
2.2 Gene-based approaches to treat inherited retinal degenerations 
Gene-therapy approaches are dependent on the type of mutation to reverse 
thus different strategies may be adopted in order to treat a gain- or a loss-of-
function mutation as well as for the treatment of a dominant-negative mutation 
or in the case of haploinsufficiency. However, such strategies can be divided in 
two distinct groups: gene replacement or gene silencing strategies. 
 
2.2.1 Gene replacement strategy 
Recessively inherited diseases typically result from alterations that eliminate the 
encoded protein (loss-of-function mutations). They can give rise to dominant 
inheritance if the remaining normal copy does not express sufficient protein to 
meet cell’s needs. Dominance resulting from inadequate expression levels is 
known as haploinsufficiency and it is extremely rare, thus for most genes, one 
allele is sufficient to preserve retinal function. For the treatment of loss-of-
function mutations, the introduction of a normal copy of the gene into the 
diseased tissue53 (gene-replacement approach) can supply the missing protein. 
This approach, for example, has been applied to a form of Leber Congenital 
Amaurosis (LCA)54, the most severe form of inherited childhood blindness. The 
target gene in this case is RPE65, which is expressed in the RPE and encodes 
for an isomerise that is essential for production of the photopigment 11-cis-
retinal32. Subretinal administration of an AAV vector containing a corrected copy 
of the RPE65 gene has shown to restore vision in mice and dogs harbouring a 
mutation in the gene55-61. The recent success of clinical trials for the treatment 
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of this disease is providing sound evidence for the use of gene-based 
complementation therapeutic strategy to treat genetic recessive traits62-68. 
Gene-replacement approach has also been successfully used in animal models 
of genetically identified forms of RP, however, in this case, it is essential to 
intervene during early stages of the diseases progression in order to prevent 
the loss of photoreceptor cells.  
 
2.2.2 Gene silencing strategy 
Dominant mutations typically alter the transcribed amino acid sequence and 
result in toxic variants of the encoded protein (gain-of-function of dominant-
negative mutations). One strategy to treat these alterations is to eliminate the 
mutant gene (gene silencing approach) and hope that the remaining normal 
copy of the gene will provide sufficient functional protein. The main target of 
genetic silencing strategies is the mRNA transcript whose function can be 
inhibited by antisense-, ribozyme- and more recently by small interfering RNAs- 
(siRNAs) and miRNA-based approaches. In particular, RNAi is holding great 
promise for treating dominant diseases for its efficiency in mRNA transcripts 
cleavage in animal models of adRP due to P23H or P347S53; 69-74. An emerging 
alternative to such RNA-targeting approaches is the modulation of gene 
expression at the transcriptional level by using artificial zinc finger-based 
transcription factors (ZF-TFs) or the genomic inactivation of a disease gene by 
using targeted zinc finger-based nucleases (ZFNs)75-77. The action of such 
novel approaches is targeted to the genomic sequence, silencing the 
downstream target gene independently by the causative mutation identified; as 
a consequence they allow the development of economic viable therapeutics 
since they circumvent the mutational heterogeneity associated to diseases, 
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such as adRP due to rhodopsin mutations. Indeed, as mentioned before, 
mutations in the rhodopsin gene are the most common cause of Retinitis 
Pigmentosa (RP) among human patients and nearly all rhodopsin mutations are 
dominant (The only characterized rhodopsin recessive allele is the mutation 
E249ter42). 
 
2.3 Animal models of RP 
The study of animal models with naturally occurring degenerative retinal 
diseases has been important for the discovery of numerous candidate genes, 
some of which have led to the identification of new disease genes in humans. 
These animals are useful models for understanding molecular pathways 
activated during the disease and to test experimental therapies for this 
otherwise incurable group of defects. Furthermore, the ability to generate gene-
specific transgenic and targeted (knock-out or knock-in) mice, allows the 
creation of new models of human retinal disease and facilitate the elucidation of 
gene dysfunction. Several animal models of RP are available, mostly in 
rodents, pigs and canines78-80. Each of them shows peculiar phenotypical 
features depending on the mutated gene/allele, although all RP models are 
characterized by photoreceptors degeneration with the main differences 
consisting in the onset and time course of the disease. In this paragraph I will 
focus on the most common animal models of RP due to mutations in the 
rhodopsin gene. In 1997, Humphries and colleagues generated mice carrying a 
targeted disruption of the rhodopsin (RHO) gene81. The rod outer segments of 
Rho-/- mice do not develop fully and photoreceptor cells are lost over a 3 month 
period.  No rod ERG response is present in 8-weeks-old animals.  Rho+/- 
animals retain the majority of their photoreceptors although the inner and outer 
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segments of these cells display some structural disorganization and the outer 
segments become shorter in older mice.  The rhodopsin knock-out animals 
provide a useful genetic background on which to express other mutant opsin 
transgenes as well as assessing the therapeutic potential of re-introducing 
functional rhodopsin genes into degenerating retinal tissues. The P23H 
mutation is the most prevalent mutation in human adRP patients in US82. 
Twelve percent of American patients with autosomal dominant Retinitis 
Pigmentosa (adRP) carry a substitution of histidine for proline at codon 23 
(P23H) in their rhodopsin gene, resulting in photoreceptor cell death from the 
synthesis of the abnormal gene product. Transgenic rodents and pigs 
overexpressing the dominant P23H rhodopsin mutations that recapitulate the 
human disease have been generated83-87. Transgenic mice containing the 
P23H mutation appear to develop normal photoreceptors, but their light-
sensitive outer segments never reach normal length85. With advancing age, 
both rod and cone photoreceptors are progressively reduced in number. The 
degeneration of the transgenic retina is associated with a gradual decrease of 
light-evoked electroretinogram responses. The disease mechanism associated 
with the P23H mutation remains unclear. Haploinsufficiency is unlikely, since 
humans and mice heterozygous for rhodopsin null mutations do not show 
clinical evidence of RP, although they may present with electrophysiological 
abnormalities42; 81; 88; 89. In addition, transgenic animals overexpressing the 
P23H allele on a wild-type rhodopsin background present with retinal 
degeneration. Overexpression of wild-type rhodopsin in P23H transgenic mice 
slows the progression of retinal degeneration, indirectly suggesting a dominant-
negative effect of the mutated allele90. Several independent observations point 
to a gain-of-function effect exerted by the P23H mutation. Its overexpression in 
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cultured cells results in its accumulation in the endoplasmic reticulum (ER) as a 
consequence of the incorrect folding of the mutated protein91. In the ER, 
misfolded P23H aggregates and overwhelms the proteasome system, leading 
to cell death91; 92.  
Mutations resulting in changes in the C-terminal domain of rhodopsin result in 
some of the more severe forms of the disease, with total blindness occurring in 
early adulthood. The rhodopsin C-terminal sequence is recognized by specific 
factors in the trans-Golgi network. Mutations resulting in changes in this region 
produce RP due to formation of abnormal post-Golgi membranes and from the 
aberrant subcellular localization of rhodopsin93-95. Among the class I mutants, 
those affecting the proline in position 347 near the C-terminus seems to be 
extremely deleterious. This residue is conserved among all known visual 
pigments. Six different missense mutations affecting this residue have been 
identified among patients with RP, indicating that proline-347 mediates some 
vital function of rhodopsin. Proline-347 mutants are of particular interest, since 
no functional abnormalities of the mutant proteins have been observed in in 
vitro studies, yet they tend to cause a more severe form of RP than that found 
in patients with adRP due to other mutations96. A transgenic mouse carrying a 
human P347S allele was generated to investigate the early pathogenic events 
by which this rhodopsin mutant leads to photoreceptor cells death94. In the pre-
degenerate or early degenerating retinae of these mice there was no gross 
perturbation of phototransduction, as monitored by ERGs, and no accumulation 
of mutant rhodopsin. However, the mutant retinae exhibited a distinct 
morphological phenotype (extracellular accumulation of small rhodopsin-
containing vesicles in the vicinity of basal outer segments and apical inner 
segments) which suggests that the C-terminus of rhodopsin might have a role 
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in rhodopsin transport to the outer segments95. Photoreceptor cell death in the 
P347S mice can be thus a consequence of this primary defect.  
To further elucidate the mechanisms of photoreceptor cells death induced by 
rhodopsin mutations, also transgenic porcine model for the rhodopsin P347L 
and P347S mutations have been produced and show a disease phenotype 
similar to that found in humans86; 97; 98. 
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3. ADENO-ASSOCIATED VIRUS (AAV) AS A TOOL FOR IN VIVO GENE 
TRANSFER 
The success of gene therapy approach is based on an appropriate amount of a 
therapeutic gene delivered into the target tissue without substantial toxicity. 
Each viral vector system is characterized by an inherent set of properties that 
affect its suitability for specific gene therapy applications. For some disorders, 
long-term expression from a relatively small proportion of cells would be 
sufficient (for example, genetic disorders), whereas other pathologies might 
require high, but transient, gene expression. 
To date, three types of viruses have mainly proven useful for retinal transgene 
delivery. They are Adeno-Associated Virus (AAV), Lentivirus and Adenovirus53; 
99. These viruses are genetically modified to eliminate the inherent toxicity 
caused by their ability to replicate and disseminate51. Among these vector 
systems AAV-based vectors are very promising. AAVs are not associated with 
human diseases and possess a number of properties that make them 
particularly suitable for clinical gene therapy, including the efficiency to transfer 
genetic material to a number of dividing and not dividing cells and a natural 
propensity to persist in human cells. In addition, the development of AAV 
vectors for gene therapy so far has shown an excellent safety record with data 
accumulated from thousands of animal studies and hundreds of human 
patients51; 100. 
 
3.1 General overview on AAV 
The adeno-associated virus (AAV) is a small (20-25 nm in diameter), non-
enveloped, icosahedric Dependovirus belonging to the Parvoviridae family101. 
These viruses are non pathogens for humans and possess a linear, single-
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stranded DNA genome that can replicate in the presence of different helper 
viruses such as adenovirus, herpesvirus or papillomavirus102. AAV was 
originally isolated as a contaminant of adenoviral cultures and thus given the 
name adeno-associated virus. It is native of humans and non-human primates 
(NHP) and exists in nature in more than 100 distinct variants, including both 
those defined serologically as serotypes and those defined by DNA sequence 
as genomovars103; 104. The AAV genome (4.7 Kb) consists of two open reading 
frames: i) rep, which codes for a family of multifunctional non-structural proteins 
that are involved in viral genome replication, transcriptional control, integration 
and encapsidation of rAAV genomes into preformed capsids105-109 and ii) cap 
encoding for the three structural proteins VP1, VP2 and VP3110; 111. rep and cap 
are flanked by viral T shaped palindromic elements, the inverted terminal 
repeats (ITRs) which are 145 nucleotides in length102. In vitro experiments 
demonstrated that, in the absence of an helper virus, AAV establishes latency 
by integrating in a site-specific manner in the human chromosome 19q13.3-qter 
(in a site called AAVS1)112 through an interaction between the ITRs and the 
AAVS1 locus mediated by the rep proteins113. Despite the presence of a 
preferential integration site, the status of AAV genomes from infected cells has 
been shown to be mainly episomal114; 115. 
 
3.2 Advantages and limitations of recombinant AAV (rAAV) 
The conversion of an AAV isolate into recombinant vector (rAAV) to be used in 
gene therapy is obtained by exchanging the viral coding sequence between the 
ITRs with the therapeutic gene116. To produce rAAV, the rep and cap functions 
as well as the helper genes needed are provided in trans117. In the absence of 
rep, rAAV loses its site-specific integration ability118. The most commonly used 
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strategy to produce rAAV vectors to be used in gene therapy is based on the 
co-transfection into permissive cells (usually human embryonic kidney 293 
cells) of three separate plasmids116; 117: i) a plasmid containing the viral ITRs 
flanking the therapeutic gene cassette; ii) a packaging plasmid encoding for the 
rep and cap proteins; iii) the helper plasmid encoding for the essential 
adenoviral helper genes (Fig. 9)116; 117. The versatility of the rAAV vectors is 
that 
g  
the cap genes in the packaging plasmid can be interchanged between different 
AAV serotypes isolated (from AAV1 to AAVn) and cloned allowing the assembly 
of hybrid rAAV with the vector genome (encoding the therapeutic gene) from 
one serotype (the most studied and commonly used is for example the genome 
from AAV2) and the capsid from a different AAV serotype119; 120. These hybrid 
vectors are named rAAVx/y where x indicates the serotypes of origin of the 
genome and the y is the capsid119. Since capsid proteins are the main 
determinants of rAAV tropism and transduction characteristics (intensity and 
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onset of gene expression)121; 122, vectors with different capsids have different 
abilities to transduce target cells in vivo (Fig. 9). This can be partly explained by 
the presence of specific receptors for AAV serotypes on the membrane of 
target cells. For example in the case of rAAV2/2, capsid proteins interact with a 
membrane receptor complex including heparin sulphate proteoglycans, 
fibroblast growth factor receptor 1 and integrin123-125, while rAAV2/5 interacts 
with O-linked sialic acid and platelet derived growth factor receptor126; 127. The 
absence of the receptor complex for rAAV2/2 on the luminal surface of airways 
epithelia and the presence of O-linked sialic acid explain the ability of rAAV2/5, 
but not of rAAV2/2, to transduce the lung in vivo128; 129. It’s highly likely that 
post-entry events can be additionally influenced by different AAV viral capsids. 
Compared to other viral vectors, rAAV induces little or no innate immunity, 
probably due to the lack of viral sequence other than the ITRs130. In addition, 
rAAV generally elicits a reduced cellular immuno-response against the 
transgene product, probably due to the inability of rAAV vectors to efficiently 
transduce or activate mature antigen presenting cells (APCs)131. Both the 
humoral and cell-mediated response to the delivered transgene depend on a 
number of variables including the nature of the transgene itself, the promoter 
used, the route and site of administration, the vector dose and the host 
factors132-134. The majority of these variables can be suitably modified. Humoral 
and, more recently, cell-mediated immune responses to the rAAV virion capsid 
have been consistently detected in animals and humans following rAAV vector 
delivery103; 104; 133; 135-137. The presence of neutralizing antibodies and cell-
mediated immunity against capsid proteins has been shown to prevent or 
greatly reduce the success of vector re-administration and to limit the duration 
of transgene expression133; 135-139. Several studies have suggested that evasion 
 34
 - Introduction - 
of the immune response against the rAAV capsid can be obtained by using 
different serotypes by capsid modification or by immunosuppression132; 134; 136. 
One of the major drawback of rAAV vectors as tools for in vivo gene transfer is 
their relatively small packaging capacity (4.7 Kb) which limits the possibility to 
develop therapies for diseases caused by mutations in large genes such as 
Duchenne muscular dystrophy, cystis fibrosis, Stargardt’s disease and 
others140; 141. Various strategies have been adopted to overcome this limitation 
taking advantage of the propensity of AAV genomes to form head-to-tail 
concatamers through intermolecular recombination108; 142-146. 
Despite this limitation, the absence of human diseases associated with their 
infection, the low toxicity and immunogenicity, the ability to transduce both 
dividing and non-dividing cells and the possibility to use a specific serotype to 
transduce a target tissue make rAAV an ideal candidate vehicle for gene 
therapy applications in vivo. 
 
3.3 rAAV as a gene transfer vehicle for the retina 
rAAV are promising vectors for gene therapy in the retina since they can 
transduce dividing and non-dividing cells102, mediate efficient and prolonged 
transgene expression147; 148 and are able to transduce the retina with a different 
cell tropism and efficiency119. To date, rAAV vectors have been used to improve 
the efficiency of transduction in different retinal cell layers121; 149; 150 which are 
affected in many inherited and non-inherited blinding diseases28. Subretinal 
injections of rAAV2/2, rAAV2/5, rAAV2/7 and rAAV2/8 in rodents result in 
efficient transduction of photoreceptor cells and RPE cells121; 151. rAAV2/5-
mediated transduction peaks 5 days post-treatment, when rAAV2/2 begins to 
express. Another characteristic of rAAV2/5 is that it is able to transduce a 
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considerably higher number of photoreceptors than rAAV2/2 (with a ratio of 
400:1, 15 weeks after transduction) reaching a number of genomic copies per 
eye 20 folds higher than rAAV2/2121; 150. Interestingly, rAAV2/7 and rAAV2/8 
mediated six to eight fold higher levels of in vivo photoreceptor transduction 
than rAAV2/5151. Many of the features of rAAV-mediated retinal transduction in 
rodents have been validated in feline, canine and non-human primates (NHP) 
models55; 56; 147; 152-155. In NHP, rAAV2/2 efficiently targets rod cells and RPE 
and is not able to transduce cones, whereas rAAV2/5 appears to be more 
efficient than rAAV2/2 in transducing rod photoreceptors147; 154. The RPE has 
been efficiently transduced by subretinal injections of rAAV2/4 that seems 
exclusive for this cell type, in which it allows a stable transgene expression in 
rodents, canines and NHP150; 156. rAAV2/1 and rAAV2/6 exhibit a higher RPE-
transduction specificity and efficiency and a faster expression than rAAV2/2121; 
150. rAAV2/3 poorly transduces the retina following subretinal administration, 
possibly due to the absence of a specific receptor or co-receptor essential for 
capsid interaction with cellular membrane156. rAAV2/2 is the only rAAV vector 
able to efficiently transduce retinal ganglion cells, the trabecular meshwork and 
different cells of the inner nuclear layer, upon intravitreal injections150; 157. rAAV 
vectors can efficiently transduce neuroprogenital retinal cells, with transduction 
characteristics depending on the time of administration. For example, subretinal 
injection of rAAV2/1 at embryonic stage 14.5 (E14.5) results in expression of 
the transgene in various cell types while if given at post-natal day 0 (P0), the 
transgene expression is confined to the RPE and photoreceptors158. Similarly, 
fetal retina is barely transduced by rAAV2/2 while the same vector can 
transduce various retinal cell types if administered soon after birth; finally while 
subretinal fetal administration of rAAV2/5 results in transduction of cone 
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photoreceptors, amacrine and ganglion cells, when given at birth it transduces 
both cones and rods as well as Mueller cells158. 
In addition, to restrict transgene expression to particular cell types in the retina, 
the use of tissue-specific promoters can be exploited. Among them, promoter 
fragments as well as cis-acting elements from the RPE65 or VMD2 genes have 
been coupled to the proper rAAV serotype to target RPE55; 159. In 1997 Flannery 
and colleagues148 used the proximal promoter region of the mouse rod opsin 
promoter located within -385 to +36 (RPPR) to restrict rAAV2/2 expression 
specifically to rat photoreceptors. Moreover, Glushakova and collaborators160 
have shown that this promoter is photoreceptor specific but not rod-specific: 
subretinal injections in rats of rAAV2/5 expressing RPPR-driven eGFP resulted 
in both rods and cones transduction, suggesting that new insights are 
necessary in order to achieve specific transgene expression in photoreceptors. 
Thus, in order to think to the development of a rAAV vector as gene therapy 
vehicle to delivery transgene product to a target cell, it is extremely important to 
consider which capsid to use, the promoter element and the route of 
administration of the vector. To date, among the vectors tested, the best 
combination in terms of transduction efficiency and transgene expression levels 
into photoreceptor cells can be obtained using a rAAV2/8 and the human 
rhodopsin promoter. These date rise from the experiments performed by 
Allocca and colleagues, a study in which I took part151. 
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4. ZINC-FINGER-BASED ARTIFICIAL TRANSCRIPTION FACTORS (ZF-ATFS) 
A variety of biological processes including development, differentiation and 
diseases are regulated through gene expression which is mainly modulated by 
transcription factors. These proteins are able to bind to specific sites on the 
promoter region of target genes thus controlling their expression. This in 
principle suggests that the generation of “artificial” transcription factors (ATFs) 
tailored to the promoter of a given gene enable the transcriptional control of the 
target thus impacting on the downstream process. This idea paves the way for 
the development of novel gene therapy approaches aimed at controlling the 
expression of a disease gene. 
Transcription factors are protein mainly composed by three elements: i) a DNA 
binding domain (DBD); ii) an effector domain to control the expression of the 
target; iii) a nuclear localization signal (NLS) to deliver the transcription factor to 
the nucleus where the transcription mechanism occurs. Many proteins are able 
to bind DNA but zinc finger proteins (ZFPs) have been chosen for the 
generation of artificial transcription factors on the basis of their plasticity, 
modularity and because they bind the DNA as monomer. This is a very 
important characteristic since usually promoter regions have no palindromic 
sequences. One of the most common zinc finger-based DBD in eukaryotes is 
the Cys2His2 type zinc finger domain which comprises multiple repeats of 
approximately 30 amino acids with a simple  fold stabilized by hydrophobic 
interactions and the chelation of a single zinc ion (Fig. 10). It was first 
discovered in the transcription factor TFIIIA of Xenopus laevis in 1985161. 
Classically, one unit of the Cys2His2 zinc-finger domain was thought to contact 
3-bp of the DNA target. Pabo's group reported the X-ray crystal structure of the 
DNA complex with the endogenous transcription factor Zif268 at 2.1 A 
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resolution162. In the complex, amino acids at positions −1 and 6 of the α-helical 
region of the zinc-finger domain (position 1 is the starting amino acid in the α-
helix) in the 1st and 3rd  fingers 
contacted the 1st and 3rd bases, 
and amino acids at positions −1 
and 3 in the 2nd  finger contacted 
the 1st and 2nd bases. However, 
no other amino acid–base contact 
was observed at that resolution. 
After Pabo's reports, Berg's group 
reported important structural 
information on DNA recognition by 
ZFPs. They revealed the crystal structure of the DNA complex of their designed 
ZFP at 2.2 A resolution163. The ZFP comprising a consensus finger 
framework164 was selected from a family of three-fingers proteins that had been 
prepared and characterized with regard to their DNA-binding specificities165-168. 
The X-ray crystal structural analysis of the DNA complex revealed the following 
important features: i) each zinc-
finger domain recognizes an 
overlapping 4-bp DNA 
sequence, where the last base 
pair of each 4-bp target is the 
first base pair of the next 4-bp 
target (Fig. 11); ii) in all three 
fingers of the protein, amino 
acids at specific positions 
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contact DNA bases at specific positions in a regular fashion. Namely, amino 
acids at positions −1, 2, 3, and 6 contact the 3rd, 4th, 2nd, and 1st bases of the 
overlapping 4-bp DNA targets, respectively (only the 4th base in the antisense 
strand; Fig. 11). Whether a one-finger domain recognizes a 3- or 4-bp DNA 
remains unclear and many papers and reviews still report that one zinc-finger 
domain recognizes 3- or 4-bp. 
In 1992, Berg's group reported the first example of ZFPs with altered binding 
specificities169. They mutagenized the amino acid at position 3 of the 2nd finger 
of the protein Sp1 based on a database of zinc-finger sequences available at 
the time and presented a first partial “recognition code” of GNG and GNT 
triplets. After these pioneering studies, several groups reported the generations 
of ZFPs with new DNA-binding specificities making the generation of ZFP-
based ATFs practical. 
 
4.1 Generation of ZF-ATFs 
The most practical way to obtain effective ATFs is to screen a panel of ATFs 
that individually target different sequences in the promoter region of the gene of 
interest in a high-throughput manner170. As a consequence, the first step in the 
generation of a ZF-ATFs is the choice of the endogenous target gene to 
modulate. To allow the ATFs to bind the desired target, the accessibility of 
genomic DNA in chromatin is crucial171. Moreover, an important aspect is that 
the ATF would be targeted to a unique site in the genome and this can be 
achieved using long DNA target sequences. Assuming that a single ZF module 
binds 3-bp, it is therefore theoretically necessary to recognize >16-bp DNA for 
specific recognition of a single DNA target site in a human cell considering that 
the genome size is 3×109 bp. As a consequence, at least 6 ZF modules should 
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be joined together in order to recognize a DNA target site of 18-bp. To date, a 
recognition code table has been generated which allows to recognize 49 of the 
64 DNA triplets172-176 and the modular assembly of the DBD can be also 
facilitated through the use of the Zinc Finger Tools website based on Barbas’ 
modules (http://www.zincfingertool.org)177. Moreover, two-finger building blocks 
made by Sangamo Bioscience are commercially available via Sigma-Aldrich76. 
Once that a panel of ZF-based DBDs targeted to the desired gene are 
obtained, they could be expressed and purified in order to examine their binding 
properties determining the apparent dissociation constant (Kd) through 
techniques such as Electromobility Shift Assay (EMSA). The best or better 
DBDs are fused to a nuclear localization signal (NLS), to an epitope tag such as 
FLAG, c-myc or HA to monitor ATF expression, and to an effector domain to 
generate ATFs. The most frequently used transcriptional activator is the VP-64 
domain178 while the most popular transcriptional repressor is a Kruppel-
associated box (KRAB) domain of KOX1179. Finally, the resulting ATFs are then 
cloned into mammalian expression plasmids or viral vectors and their 
functionality is investigated by transient reporter assays or more ideally by 
analyzing the mRNA levels of target genes by Northern blotting or quantitative 
real-time PCR. The efficacy and the specificity of the ATFs can be evaluated by 
microarray analysis, DNase I footprinting assay or chromatin 
immunoprecipitation (ChIP). 
 
4.2 ZF-ATFs applications 
The first study of gene regulation by altered transcription factors in living cells 
(yeast) was reported in 1992180. Since then, several groups spent their effort in 
order to develop this technology to achieve the transcriptional control at will of a 
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given gene with therapeutic purposes. The first 6-finger ATF was reported in 
1998178 to modulate the expression of the ErbB-2 which is overexpressed in a 
high percentage of human adenocarcinomas. A 6-finger ATF targeted to the 
promoter region of the ErbB-2 gene was generated and demonstrated a 
successful and specific up- and down-regulation of the target gene in vitro.  The 
first example of ATF-mediated gene regulation in vivo was reported in 2002181 
in a study sponsored by Sangamo Bioscience, a biotechnology company 
worldwide leader in the design and development of engineered zinc finger 
DNA-binding proteins (ZFPs) for gene regulation and gene modification). They 
designed ZFPs to regulate the endogenous gene encoding vascular endothelial 
growth factor-A (VEGF-A) which is an endothelial cell-specific mitogen that is a 
key inducer of new blood vessel growth, both during embryogenesis and in later 
processes such as wound healing. VEGF-A levels are dramatically increased 
by hypoxia, triggering angiogenesis and microvascular permeability. Therefore, 
both activation and repression of VEGF-A are attractive therapeutic 
approaches. They showed that expression of these new ZFPs in vivo led to 
induced expression of the protein VEGF-A, stimulation of angiogenesis and 
acceleration of experimental wound healing181 thus establishing for the first time  
the feasibility and potential utility of this approach as new tool for gene therapy. 
Two years ago, ZF-based ATFs entered phase II clinical trials76. 
 - Aims - 
AIMS 
The aim of the project of my Ph.D. project was the development of a novel gene 
therapy approach for the treatment of inherited retinal degenerations due to 
gain of function mutations. We developed a strategy based on zinc finger 
technology to repress the expression of the rhodopsin, the gene most 
commonly associated with autosomal dominant Retinitis Pigmentosa, a severe 
inherited retinal degeneration with a prevalence of 1:3500 worldwide. The 
possibility to silence transcriptionally rhodopsin would allow to prevent the 
pathological consequences of the expression of the mutated allele, thus halting 
the patho-physiological cascade of events that lead to retinal degeneration. The 
strategy employed is mutational-independent because transcriptional silencing 
does not discriminate between the mutated and wild-type alleles. Thereby, 
based on this characteristic feature, in principle any gain of function mutation 
can be treatable; however, since also the wild type allele is silenced, a 
combined repression and replacement system will be developed in the future. 
The specific aims of my project were the following: 
 
1. Generation and characterization of engineered zinc finger 
transcriptional repressors targeted to the human rhodopsin promoter. 
To control the expression of the rhodopsin gene we generated a series of 
polydactyl ZF-based transcription factors fused either to an activator (VP64) 
or to a repressor (KRAB) in order to modulate the expression of the target 
gene.  
2. Assessment of the efficacy of RHO transcriptional repression in vivo 
and impact on the disease progression in an adRP mouse model. 
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Based on in vitro data in aim 1 I selected a ZFR and enclosed it in an 
AAV2/8 vector for photoreceptor delivery in a mouse model of adRP 
expressing a mutated human rhodopsin (P347S). This animal model 
develops retinal degeneration with fast progression. The levels and 
specificity of transcriptional repression were measured. In vivo expression of 
the ZFR in the diseased photoreceptor resulted in the specific 
downregulation of the transgenic human rhodopsin leaving unaltered the 
expression levels of the endogenous murine allele. This in turn ameliorated 
the retinal phenotype functionally and morphologically as measured by 
electroretinograms and histological the progression of the disease. 
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MATERIALS AND METHODS 
 
Rational design of the artificial Zinc-Finger based Transcription Factors 
(ZF-TFs) 
The protein sequences of the DNA Binding Domains (DBDs) targeted to the 10 
different target sites (see Table 2 in Results section) were obtained using the 
web-based Zinc Finger Tools (http://www.zincfingertools.org). Each DBD was 
composed of two arms each recognizing a 9-bp half target site and fused 
together through a linker sequence in order to overcome the gap sequence. We 
used two different linkers according to the length of the gap: for gaps longer 
than 3-bp (target sites from 1 to 4) we used a complex structured linker, as 
reported by Moore186 (GRSSVESACVTSVLVALLPATSAPTQVSG) while for 
longer gaps (target sites from 5 to 10) we used a flexible linker, as described by 
Rebar181 (QNKKGGSGDGKKKQHA). We optimized the corresponding DNA 
sequences to facilitate the subsequent cloning steps and purchased them as 
transgene in the pLS-standard vector at “TOP Gene Technologies”, Quebec, 
Canada. After the in vitro selection steps, we purchased an additional DBD with 
the fingers of the DBD number 6 shuffled (from 1.2.3-4.5.6 to 5.1.6-3.4.2) to be 
used as a negative control for a total of 11 DBDs. All the DBDs were flanked by 
a ClaI and an XbaI site at the 5’ and 3’ end, respectively. 
DBD number 1 was purchased as a complete protein fused at the N-Ter with 
the repressor domain KRAB (Krüppel-associated box, 
DAKSLTAWSRTLVTFKDVFVDFTREEWKLLDTAQQILYRNVMLENYKNLVSLG
YQLTKPDVILRLEKGEEPWLVEREIHQETHPDSETAFEIKSSV) and the nuclear 
localization signal (NLS, PKKKRKV) from SV40 large T antigen and fused at 
the C-Ter with the HA-tag (YPYDVPDYAS). Also DBD number 2 was 
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purchased as a complete protein but fused at the C-Ter with the NLS, the 
activator domain VP64 (tetrameric repeat of herpes simplex VP16’s minimal 
activation domain, 
GRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLD
MLIN) and the HA-tag. In the two proteins, the DBDs can be exchanged 
through a double digestion with the restriction endonucleases ClaI and XbaI. 
The 11 different transcription activators (ZF-As) and repressors (ZF-Rs) were 
inserted in the pAAV2.1-CMV-EGFP NotI and HindIII sites, downstream of the 
CMV (Cytomegalovirus) promoter by removing the EGFP coding sequence for 
transfection experiments. For AAV preparations, ZF-R6 was inserted in the 
pAAV2.1-RK-EGFP NotI and HindIII sites, downstream of the RK (Rhodopsin 
Kinase) promoter by removing the EGFP coding sequence. For retrovirus 
preparations used in Retinal Stem Cell experiments, coding sequences of ZF-
R2, ZF-R6 and ZF-R6 shuffled were cloned in LXSN plasmid EcoRI and HindIII 
sites downstream of the CMV promoter. 
 
Reporter Constructs 
Luciferase reporter plasmids were generated from the pGL3-Basic vector 
(Promega, Madison, WI) by cloning the proximal upstream regions of the 
human or murine rhodopsin gene. The human rhodopsin promoter (hRHO-P) 
extending from -330 to +92 relative to the transcription start site was PCR 
amplified using the FastStart High Fidelity PCR System (Roche) from a human 
genomic DNA sample using the following primers: hRHO-P.Nhe forward 5’-
TTTTGCTAGCTGTCCAGAGGACATAGCAC-3’ and hRHO-P.EcoRV reverse 
5-AAAGATATCGGCTGTGGCCCTTGTGGCTGA-3’. For the murine rhodopsin 
promoter (mRho-P) extending from -404 to +96 we used a murine genomic 
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DNA sample and the following primers: mRho-P.Nhe forward 5’-
TTTTGCTAGCTCAGATCTGTCAAGTGAGCC-3’ and mRho-P.HindIII reverse 
5’-AAAAAGCTTGGCTGCGGCTCTCGAGGCTG-3’. The two fragments were 
inserted within the NheI/SmaI or NheI/HindIII sites of pGL3-basic vector 
obtaining pGL3-hRHO-P-Luciferase or pGL3-mRho-P-Luciferase, respectively. 
 
Selection of the functional ZF-TFs in human cells by transient transfection 
HEK293 cells were plated in 6-well plates at a density of 400.000 cells/well. 
Twenty-four hours later, the cells were co-transfected using FUGENE 6 (Roche, 
Basel, Switzerland) following the manufacturer’s instructions. Transfection 
cocktails included 200ng of reporter plasmid (or pGL3basic as a negative 
control), 300 ng of ZF-TF, 300 ng of a plasmid encoding for the murine CRX 
(alone as a positive control in transactivation assay or in combination with the 
ZF-Rs for the repression assays) and 10 ng of Renilla Luciferase reporter 
plasmid control (Promega) to normalize for transfection efficiency. The amount 
of DNA was kept constant by adding pAAV2.1-TBG-EGFP to a total of 1 g. 
Cells were harvested 48 h after transfection in 1x PLB Lysis Buffer (Promega). 
Firefly and Renilla Luciferases activities were measured in a GloMaxTM 
luminometer (Promega) using Dual-Luciferase Reporter Assay System 
(Promega). 
 
Electromobility Shift Assay (EMSA) 
HEK293 cells were transfected with a plasmid encoding the ZF-R2, ZF-R6 or 
ZF-R6 shuffled using FUGENE 6 as described above. After 48 h, cells were 
harvested and nuclear extracts were prepared using NE-PER Nuclear and 
Cytoplasmic extraction kit (Pierce) according to the manufacturer’s instructions. 
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The presence of the proteins in the nuclear fractions was assessed by Western 
Blotting analysis using as primary antibody a rabbit anti-HA (1:100; SIGMA, 
Milan, Italy). Electromobility Shift Assay was performed using Lightshift 
Chemiluminescent EMSA kit (Pierce) following the manufacturer’s instructions. 
In brief, nuclear extracts (ZF-R2, ZF-R6 or ZF-R6 shuffled) were incubated with 
equal amounts (20 fmol) of the specific byotinilated double stranded probe (5’-
TGTGGGGGTTAGAGGGTCTACGACTA-3’) to asses the specific shift for 20 
min at room temperature. The competition control was performed adding a 
molar excess of the unlabeled probe to the mix. The sequence of the unspecific 
was the following: 5’-TGCGGCGGCTAAAGGCTCGACAACGA-3’. The 
supershift was obtained adding a rabbit anti-HA (1:100; SIGMA, Milan, Italy) 
primary antibody at the mix. 
 
AAV vector production and purification 
AAV vectors were produced by the TIGEM AAV Vector Core using pAAV2.1-
RK-ZF-R6 and pAAV2.1-CMV-EGFP. Recombinant AAV8 viruses were 
produced by triple transfection of HEK293 cells followed by CsCl2 purification of 
the vectors, as previously described121. For each viral preparation, physical 
titers (GC/ml) were determined by both PCR quantification using TaqMan 
(Perkin–Elmer, Life and Analytical Sciences, Inc.) and dot-blot analysis. 
 
RNA preparation and measurement of rhodopsin transcript levels by Real 
Time PCR 
RNAs from tissues or cells were isolated using TRIZOL reagent (Invitrogen) 
according to the manufacturer’s protocol. cDNA were amplified from 500 ng of 
isolated RNA using the SuperScript™ III First-Strand Synthesis (Invitrogen) as 
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indicated in the attached instructions. Transcripts levels of human and murine 
rhodopsin were measured by Real Time PCR using the ABI Prism 7000 
Sequence Detection System (Applied Biosystems, Foster City,CA) and the 
following primers: hRho_forward 5’…CCGGCTGGTCCAGGTACAT….3’ and 
hRho_reverse 5’…TTGTTGACCTCCGGCTTGAG…3’; mRho_forward 
5’…TGTTGAACAAGCAGTTCCGGA...3’ and mRho_reverse 
5’…TCGTCATCTCCCAGTGGATTC...3’. The PCRs with cDNA were carried in 
25 l total volume using 12.5 l SYBR Green Master Mix (Applied Biosystems) 
and 400 nM primers under the following conditions: preheating, 50°C for 2 min 
and 95°C for 10 min; cycling, 40 cycles of 95°C for 15 s and 60°C for 1 min. All 
the reactions were standardized against murine GAPDH by using the following 
primers: mGAPDH_forward 5’…CTTCACCACCATGGAGAAGGC…3’ and 
mGAPDH_reverse 5’…CTCATGACCACAGTCCATGCC…3’. To quantify 
expression levels of photoreceptor specific genes (Peripherin, PDE6and 
Cnga) we used the following primers: for Peripherin: mPeriph.forward 5’-
CGGGACTGGTTCGAGATTC-3’ and mPeriph.reverse 5’-
ATCCACGTTGCTCTTGATGC-3’; for PDE6: PDE6.forward 5’-
TGAAGATGAAGATGTTTTCACG-3’ and PDE6.reverse 5’-
CTCTGCGTGTCTCACAGTTG-3’; for Cnga: Cnga.forward 5’-
ACTCGTACAAAAGGCGAGGAC-3’ and Cnga.reverse 5’-
CTTTGTTGCTGCTGTTGTTGAC-3’. Each sample was analyzed in triplicate in 
two independent experiments.  
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Retinal stem cells culture and analysis 
All procedures on mice (including their euthanasia) were performed in 
accordance with the ARVO Statement for the Use of Animals in Ophthalmic and 
Vision Research and with institutional guidelines for animal research. 
Retinal stem cells were isolated from adult P347S mice and were incubated for 
5 days until floating spheres formed in serum free medium (0.6% glucose and 
N2 hormone mix in DMEM-F12) containing 20 ng/ml basic FGF supplemented 
with 2 µg/ml heparin (Sigma, Milan, Italy), as previously described. Retinal 
floating spheres were allowed to differentiate on eight well glass slides that 
were coated with extracellular matrix (ECM, Sigma) in DMEM-F12, 
supplemented with 1% FBS (Gibco, San Giuliano Milanese, Italy). Analysis was 
performed 12 days after induction of differentiation. Apoptotic nuclei were 
detected by TdT-dUTP terminal nick-end labeling kit (TUNEL, Roche 
Diagnostics, Monza, Italy) according to the manufacturer’s protocol.  For 
immunofluorescence staining, cells were washed once with PBS and then fixed 
for 10 min in PBS containing 4% PFA. After fixation, cells were washed and 
incubated 5 min in sodium citrate buffer 0.1M containing 0.2 % Triton X100. 
Blocking solution containing 3% bovine serum albumin (Sigma, Milan, Italy) was 
applied for 1 h. Primary antibodies were diluted in PBS and incubated 90 min at 
RT. The primary antibodies used were: rabbit anti-HA (1:100; SIGMA, Milan, 
Italy) and mouse anti rhodopsin 1D4 (1:400; SIGMA, Milan, Italy). Cells were 
then washed in PBS and incubated with secondary antibodies: 1:1000 Alexa 
Fluor® 568 anti-rabbit, 1:1000 Alexa Fluor® 568 anti-mouse (Molecular 
Probes), and 1:500 Cy5 anti-rabbit (Jackson Immunoresearch, West Grove, 
PA, USA). Slides were coverslipped with Vectashield (Vector laboratories, 
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Burlingame, CA, USA) and photographed using either an Axioplan microscope 
(Zeiss) or a Leica Laser Confocal Microscope System.  
To allow ectopic expression in differentiated retinal cells, ZF-R2, ZF-R6 and ZF-
R6 shuffled were cloned in Moloney murine leukemia virus-based vector LXSN 
as described above (see first paragraph of this section). Retinal cell cultures 
were transduced at day 7 post explant with retroviruses and cells were 
analyzed 4 days later. 
 
Animal model, vector administration, and tissue collection 
All procedures were performed in accordance with institutional guidelines for 
animal research. P347S +/+ animals for breeding were kindly provided by Dr. 
G. Jane Farrar (Smurfit Institute of Genetics, Trinity College Dublin, Dublin, 
Ireland) and were bred in the animal facility of the Biotechnology Center of the 
Cardarelli Hospital (Naples, Italy) with C57BL/6 mice (Charles Rivers 
Laboratories, Calco, Italy) to obtain P347S +/- mice. At P4, animals were 
anesthetized on ice and subretinally injected in the right eye with 1 l AAV2/8-
RHOK-ZF-R6 vector (6.3*1012 GC/ml) and 1 l of AAV2/1-CMV-EGFP (6.0*1012 
GC/ml) in mix whereas the contralateral eye received, as control, the same 
dose of AAV2/1-CMV-EGFP and AAV2/8-RHOK-EGFP vectors in mix. Mice 
were sacrificed at postnatal day 18 or at 1 month of age (P18 or P30). For 
morphological studies, eyecups were harvested, fixed by immersion in 4% 
paraformaldehyde and then embedded in OCT (kaltek). For RNA extractions, 
the isolated retinae were removed and snap-frozen in liquid nitrogen and 
treated as described in the above RNA preparation section. 
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Histological analysis 
For each eye, 150 to 200 serial sections (5-m thick) were cut along the 
horizontal plane; the sections were progressively distributed on 10 glass slides 
so that each slide contained 15 to 20 sections representative of the whole eye 
at different levels. Slides were coverslipped with Vectashield containing DAPI 
(4',6-diamidino-2-phenylindole; Vector laboratories, Burlingame, CA, USA) to 
stain cells nuclei and retinal histology was analyzed an Axioplan microscope 
(Zeiss). To quantify photoreceptor rescue, the number of nuclei in the outer 
nuclear layer (ONL) of each eye was counted. For each section, the number of 
nuclei in the ONL was separately counted on the nasal, central, and temporal 
sides. The nasal, temporal, and central counts of each section were 
independently averaged, therefore obtaining a number that was the average of 
the three sides for each eye. The counts from each group (treated and 
untreated) were then averaged and standard errors were calculated. 
 
Electroretinogram measurements 
ERGs were performed at P30, P60 and P90. Briefly, animals were adapted to 
the dark for 3 h and then anesthetized and accommodated in a stereotaxic 
apparatus under dim red light. ERGs were evoked by flashes of different light 
intensities ranging from 10-4 to 20 cd.s/m2 generated through a Ganzfeld 
stimulator (Lace). To minimize the noise, three different responses evoked by 
light were averaged for each luminance step. The electrophysiological signals 
were recorded by gold plate electrodes inserted under the lower eyelids. 
Electrodes in each eye consisted of a needle electrode inserted subcutaneously 
at the level of the corresponding frontal region. The different electrodes were 
connected to a two-channel amplifier. Amplitudes of a-and b-waves were 
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plotted as a function of increasing light intensities. After completion of 
responses obtained under dark-adapted conditions the recording session 
continued with the aim to dissect the cone pathway mediating the light 
response. To this end the ERG in response to light of 20 cd.s/m2 was recorded 
in the presence of a continuous background light (background light set at 50 
cd/m2). The amplitude of the b-wave for each eye was plotted as a function of 
luminance under scotopic and photopic conditions. For each group the mean b-
wave amplitude was plotted. 
 
Statistical analysis 
Data are expressed as mean ± s.e.m. as indicated and compared by two-tailed 
Student’s t-tests, two-sample equal variance. 
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RESULTS 
 
1. GENERATION AND CHARACTERIZATION OF ENGINEERED ZINC FINGER 
TRANSCRIPTION REPRESSORS TARGETED TO THE HUMAN RHODOPSIN 
PROMOTER 
 
1.1 Design and generation of Zinc Finger-based transcription factors to 
control rhodopsin gene expression 
To control the rhodopsin gene expression we designed Zinc Finger-based 
Artificial Transcription Factors (ZF-ATFs) targeted to the human rhodopsin 
promoter (hRHO-P). We first scanned the proximal hRHO-P to identify 
amenable target regions applying the following criteria: (i) exclusivity of the 18-
bp DNA sequences in the human genome, (ii) putative accessibility to the 
chromatin environment (in proximity of known endogenous transcription factors 
binding sites)182, (iii) absence of annotated polymorphisms and (iv) divergence 
between the human and murine rhodopsin promoter target sequences. We 
selected 10 different continuous or discontinuous 18-bp target sites within the 
proximal region of the hRHO-P (from -90 to -32, relative to the transcription 
start site; Fig. 12 and Table 2) that fulfilled the 4 criteria described above. To 
obtain a DNA Binding Domain (DBD) tailored to a unique target sequence in 
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mammalian genomic DNA (3,0x109 genome size in humans), theoretically, a 
sequence longer than 16-bp is needed and this can be achieved by the 
consecutive linking of at least six ZF modules. Since individual zinc finger 
typically binds 3- or 4-bp of DNA we generated DNA-binding domains (DBDs) 
by assembling 6-fingers arrays directed to the selected 18-bp DNA sequences 
using the modular assembly method. We took advantage of an online web-
 
resource to obtain the protein sequence of the DBD specific for a given 18-bp 
target site (http://www.zincfingertool.org)176-178. This online algorithm is 
extremely user-friendly. It receives as input the target DNA sequence and it 
gives as output the protein sequence of the DBD which putatively binds the 
given target sequence. Due to the lack of availability of zinc fingers for all 
possible triplets173; 174; 176; 183; 184 and to enhance DNA binding affinity185, we 
designed 10 ZF modules with two arms, each composed by 3 zinc finger units 
(arm 1 encoding fingers 1.2.3 and arm 2 encoding fingers 4.5.6, respectively) 
bridged together by linker peptides that enable to span up to 10-bp of DNA 
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gaps between their target recognition sites (Fig. 13). For gaps longer than 3-bp 
we used the structured linker reported by Moore186, whereas for shorter gaps or 
continuous sequences we used the flexible linker reported by Rebar181 (Table 
2). We next fused the zinc finger DNA-binding domains to a nuclear localization 
signal (NLS), a C-Terminal HA-Tag and to effector domains that include either 
the herpes-simplex-virus based transcriptional activator VP64   
dhdshfgdfhf jgfhjgf 
domain187 (Zinc-Finger transcriptional activators; ZF-A) or the human-derived 
Krüppel-associated box (KRAB) repression domain179 (Zinc-Finger 
transcriptional repressors: ZF-R; Fig. 13).  
 
1.2 In vitro selection of functional ZF-Rs 
To select ZF-ATFs that are functional in hRHO-P transcriptional control, we first 
performed firefly luciferase reporter gene transactivation assays by co-
transfecting HEK293 cells with both the reporter gene driven by the human 
rhodopsin proximal promoter (-330 to +32 relative to the transcription start site), 
and the individual ZF-As. Two out of the 10 constructs, significantly 
transactivated luciferase expression to levels comparable to those obtained 
with a plasmid encoding for the endogenous rhodopsin transcription activator 
CRX (Cone-Rod Homeobox containing gene)188 (Fig. 14; n=5 from 3 
independent experiments; ZF-A2, p=0.009269; ZF-A6, p=0.008928). When 
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transfected with a luciferase expression plasmid containing the murine 
rhodopsin proximal promoter region 
(harboring several mismatches 
compared to the human counterpart), 
none of the 10 constructs were 
capable to transactivate reporter gene 
expression and results obtained for 
the selected functional activators ZF-
A2 and ZF-A6 are shown in Figure 
15. To evaluate ZFPs-mediated 
transcriptional repression, we 
assessed their ability to downregulate 
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CRX-mediated transcription through triple transfection in HEK293 cells 
including the ZF-Rs, the CRX and the reporter plasmids. Notably, ZF-R2 and 
ZF-R6, containing the same DBDs 
as ZF-A2 and ZF-A6, significantly 
reduced luciferase expression 
levels (81% and 64%, repression 
relative to CRX transactivation, 
respectively. Fig. 16; n=5 from 3 
independent experiments; ZF-R2, 
p=0.000480; ZF-R6, p=0.009053) 
similarly to the repression obtained 
with CRX DBD fused to KRAB used 
as positive control189. As a further 
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control, either activation or repression activity were completely abolished when 
exchanging the relative position of individual ZF units of the DBD 6 (from 1.2.3-
4.5.6 to 5.1.6-3.4.2; ZF-A6- or ZF-R6-shuffled; Fig. 17). In addition, 
electromobility shift assay (EMSA) showed binding specificity of ZF-R6 (Fig. 
18) to the target promoter sequence in vitro.  
hgfg  
 
1.3 ZF-Rs mediated repression of human rhodopsin in retinal stem cells 
To probe whether the two selected ZF-ATFs promote rhodopsin transcriptional 
repression in the chromosomal context, we took advantage of an in vitro system 
to differentiate retinal precursors (Retinal Stem Cells, RSC)190. Neurospheres 
derived from the murine adult ocular ciliary margin, differentiate in vitro into 
various retinal neuronal cell types, including photoreceptor precursors 
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expressing rhodopsin, beta-subunit of phosphodiesterase-6 (PDE6), and 
cGMP-gated channel (Cnga)191. We explanted neurospheres from the adult 
P347S transgenic mouse. The aforementioned mouse model of adRP harbors 
a human rhodopsin transcriptional unit (including 4kb of the proximal rhodopsin 
promoter region) of a patient carrying a P347S mutation94 in addition to the 
endogenous wild-type murine rhodopsin alleles (mRho). P347S neurospheres 
once differentiated into photoreceptors-like cells (Rho+ cells) underwent 
apoptosis with kinetics similar to that observed in another severe retinal 
degeneration model (rd-1 mouse191). Virtually all rhodopsin positive cells (Rho+ 
cells) were also TUNEL positive 12 days after adding the differentiating medium 
to P347S retinal cell precursors (Fig. 19). Thus, we expected that an efficient 
gggg  
and specific repression of the human mutated rhodopsin, combined with the 
preservation of the endogenous murine rhodopsin expression, would result in 
rescue/survival of photoreceptor precursors. To this end, we transduced P347S 
retinal precursor cells 7 days after adding the differentiating medium with 
retroviruses encoding for the selected ZF-Rs (2 and 6) or ZF-R6 shuffled as a 
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negative control. Twelve days after the induction of differentiation ~70% of cells 
expressed rhodopsin (Rho+), 98% of which were also double positive (HA+; 
Rho+) confirming that retroviruses transduce retinal cell precursors 
efficiently191. ZF-R2 or ZF-R6 transduction produced a significant 77% and 92% 
protection from cell death, respectively, whereas virtually all the ZF-R6 shuffled 
transduced cells underwent apoptosis (Fig. 20, panels A,B and D; n=2 from 2 
independent experiments; ZF-R2, p=4.54x10-11; ZF-R6, p=1.18x10-11). 
Confocal images of triple stained (HA+; Rho+; TUNEL+) samples confirmed 
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that only cells expressing ZF-R2 or ZF-R6 are protected from apoptosis (Fig. 
20, panel C). 
To assess whether protection from apoptosis was exerted through the specific 
repression of human rhodopsin transcription, we measured hRHO mRNA 
levels, 4 days after transduction. ZF-R2 and ZF-R6 transduced cells revealed a 
51% and 88% reduction of human rhodopsin transcript levels, respectively, 
compared to hRHO levels in ZF-R6 shuffled treated cells (Fig. 20, panel E; n=2 
from 2 independent experiments; ZF-R2, p=0.0133; ZF-R6, p=0.0055). These 
results show that ZFPs promote a strong human rhodopsin transcriptional 
repression in a chromosomal context, and that this, in turn, can protect retinal 
progenitors of an adRP model from apoptosis. 
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2. ASSESSMENT OF EFFICACY OF AAV-MEDIATED GENE TRASNFER OF 
ARTIFICIAL ZF-REPRESSOR TO PHOTORECEPTORS OF ADRP MOUSE 
MODEL 
 
2.1 Delivery of ZF-Rs to murine photoreceptors decrease adRP retinal 
progression 
The ZF-R6 construct, which provided robust human rhodopsin transcriptional 
repression and apoptosis protection, was selected for in vivo experiments. We 
generated an AAV2/8 vector currently considered the most efficient delivery 
vehicle for photoreceptor gene transfer151; 153; 155; 182; 192, containing the ZF-R6 
construct under the photoreceptor-specific Rhodopsin Kinase (RHOK) promoter 
element151 (AAV2/8-RHOK-ZF-R6). In homozygous P347S mice the 
overexpression of the mutated rhodopsin leads to a fast progression of retinal 
degeneration. Indeed, by P21, only 1 row of photoreceptor nuclei was 
detectable by histology. Thus, in order to decrease human P347S rhodopsin 
expression levels we crossed P347S mice with a wild-type C57BL/6 
background. The resulting progeny (P347S+/-) still overexpressed the human 
rhodopsin transgene ~1.4 folds compared to the expression derived by the two 
endogenous murine alleles (mRho) and displayed a milder retinal degeneration 
(Fig. 21).  
At P70, P347S+/- retinae still retained 5-6 rows of photoreceptor nuclei and 
residual functionality, thus allowing the evaluation of disease progression over 
time by both histology and electroretinography (ERG) analysis. We first 
assessed transcriptional repression by subretinal co-injection in P4 P347S+/- of 
1 x 109 genome copies (GC) of AAV2/8-RHOK-ZF-R6 and a vector encoding 
the Enhanced Green Fluorescent Protein (EGFP; AAV2/1-CMV-EGFP) to 
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identify the transduced retinal area. The contralateral eye received a mix of 
AAV2/1-CMV-EGFP and AAV2/8-RHOK-EGFP vectors as control. Western blot 
ggggg  gg 
analysis showed expression of ZF-R6 protein in the retina twelve days post 
injection (P18, before photoreceptor degeneration; Fig. 22, panel A). 
Quantitative real-time PCR analysis demonstrated that the EGFP positive 
portion of the retina treated with AAV2/8-RHOK-ZF-R6 displayed a significant 
~26% reduction of the hRHO transcript relative to the endogenous mRho 
compared to contralateral EGFP-treated retinae (Fig. 22, panel B; n=9 from 2 
independent littermates; p=0.002643). In contrast, the expression profile of 3 
photoreceptor specific genes was unchanged (Fig. 22, panel B; n=4). To 
evaluate whether the specific downregulation of the human rhodopsin 
transgene improved retinal function of the animal model, we recorded 
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electroretinograms (ERGs) in treated and untreated eyes one month after 
vector administration (P30). As shown (Fig. 23) the delivery of ZF-R6 to 
diseased photoreceptors resulted in an amelioration of visual function 
measured in scotopic and photopic conditions. We next evaluated the ability of 
AAV2/8-RHOK-ZF-R6 to impact on P347S photoreceptor disease progression. 
ggg  gg 
Since we noticed variability in retinal function assessed by ERG among  
different littermates, despite similar P347S rhodopsin levels, we decided to 
contextually measure base-line ERG parameters and subretinally treat the 
animals (P30) and then monitor disease progression over time (P60 and P90). 
At 1 month of age in two independent littermates both scotopic and photopic 
ERG amplitudes were measured (a-wave max: pre-treatment EGFP=84.80 ± 
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9.77; pre-treatment ZF-R6=80.52 ± 10.39; b-wave max: pre-treatment 
EGFP=347.77 ± 30.73; pre-treatment ZF-R6=320.76 ± 23.98; n=12; Fig. 24, 
panel A). At both 30 and 60 days following subretinal vector administration, the 
eyes that received AAV2/8-RHOK-ZF-R6 showed a preservation of ERG 
responses compared to control eyes, in which the degeneration led to a ~40% 
reduction of the b-wave max amplitude (P60 data not shown; P90, a-wave max: 
post-treatment EGFP=39.60 ± 7.78, p<0.01; post-treatment ZF-R6 =55.53 ± 
gg  
8.69; b-wave max: post-treatment EGFP=222.06 ± 24.54, p<0.01; post-
treatment ZF-R6 =286.82 ± 11.90; n=12; Fig. 24, panel A). In addition, 
histological analysis of mice at P90 demonstrated that ZF-R6 expression was 
also associated with a partial protection of photoreceptor degeneration (Fig. 24, 
panel B; n=3). Finally, to evaluate potential toxicity on retinal function of a 
healthy mouse retina due to ZF-R6 treatment, we subretinally injected AAV2/8-
RHOK-ZF-R6 in a cohort of 10 C57BL/6 animals. Two months after vector 
delivery neither histological abnormalities nor reduction both in a- and b-wave 
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could be measured in treated eyes compared to untreated parental eyes 
supporting the safety of this approach (Fig. 25). 
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DISCUSSION 
 
Gene therapy for the treatment of recessive inherited ocular disorders has 
proven successful. In 2008, the results published for three independent clinical 
trials carried out to treat Leber’s congenital amaurosis (LCA) due to RPE65 
mutations provided sound evidence for the use of gene therapy approaches to 
treat recessive ocular diseases62-68. By contrast, the development of therapeutic 
strategies to treat autosomal dominant retinal disorders has not proceeded at 
the same pace, largely due to their complexity. The common approaches under 
consideration for the therapy of these genetic disorders include strategies to 
modulate secondary effects associated with disease, such as factors 
influencing cell longevity or function193-195. However, many dominantly inherited 
disorders may require correction of the underlying genetic defect and the 
common strategies to this purpose mainly rely on the silencing of the disease 
gene expression through RNAi-, ribozyme- or miRNA-based approaches. An 
alternative strategy is based on the transcriptional repression of a disease gene 
using artificial transcription factors which were developed in the last ten years 
with the aim to create molecules tailored to control the expression profiles of a 
disease-causative gene. 
In this study we demonstrated that photoreceptor delivery of an AAV2/8 vector 
containing an artificial zinc finger-based transcriptional repressor (ZF-R6) 
targeted to the human rhodopsin promoter robustly repressed the target gene 
expression, and this in turn was associated with improvement of photoreceptors 
functionality and in a delay of the disease progression in P347S mouse model 
of autosomal dominant Retinitis Pigmentosa (adRP). 
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The first part of this PhD project was aimed at generating functional artificial 
transcription factors (ATFs) targeted to human rhodopsin promoter. To this end, 
we first identified the DNA sequence in the proximal rhodopsin promoter to 
serve as target for the ATFs. We established two criteria to select the target 
sequences: i) the absence of polymorphisms and ii) the accessibility of the 
target site in the chromatin environment that can both affect the binding of the 
ATFs. Respecting these criteria, we identified ten putative target sites in the 
human rhodopsin proximal promoter in a region where no polymorphisms are 
annotated and in proximity of binding sites for known transcriptional regulators 
of the rhodopsin gene. In addition, for experimental needs, we chose target 
sites in a region which is not conserved between rodents and humans 
genomes. The reason of this choice derives by the animal model available for 
our in vivo studies, the P347S mouse model. This animal carries a P347S 
human mutated rhodopsin allele in addition to the murine endogenous alleles. 
Targeting a sequence which is not conserved between mouse and man will 
allow us to be selective in modulate human rhodopsin expression leaving 
unaltered the endogenous counterpart.  
We identified ten putative target sites in the proximal rhodopsin promoter 
matching the criteria explained above and, using the modular assembly 
method, we generated ten zinc-finger based transcriptional modulator of the 
rhodopsin gene. We assessed in vitro the functionality of these ATFs by 
reporter assays and we identified two out of ten activators and repressors able 
to control rhodopsin promoter activity. Since our final goal is to downregulate 
the expression of mutated human rhodopsin causing adRP, the functionality of 
the selected repressors (ZF-R2 and ZF-R6) was further validated in another in 
vitro system which better mimic the real condition:  retinal stem cells (RSCs) 
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explanted by the P347S mouse model. Indeed, the reporter system used in the 
first screening had the main limitation to be based on an episomal system 
transfected in the cells which is largely far from the condition in which the 
promoter to be controlled is in its chromatin environment. On the other hand, 
RSCs explanted by the P347S mouse model have the advantage to harbor the 
human rhodopsin cassette in the chromosomal context thus allowing a more 
accurate validation of the ATFs functionality as compared to the episomal 
system used in the first round of selection. Furthermore, the binding ability to 
the intended target site was demonstrated by Electromobility Shift Assay 
(EMSA). 
The following part of my PhD project was to evaluate the effect in vivo of the 
delivery of the selected ZF-R6 to photoreceptors of both a mouse model of 
adRP (P347S) and of a normal mouse model (C57BL/6) in order to address 
both the efficacy and potential safety concerns, respectively. To this end, ZF-R6 
was enclosed in an AAV2/8 vector, considered to date the most efficient in 
murine photoreceptor transduction151 and delivered subretinally in diseased or 
healthy retinae. We assessed no detrimental effects, both on the functionality 
(measured by electroretinograms, ERG) and in the structure (evaluated 
histologically) of normal retinae after the treatment, suggesting that the 
approach is safe. Interestingly, the diseased retinae showed a preservation of 
retinal function compared to controls upon injection of P347S animals at birth. 
This result was also confirmed in adult animals in which we monitored the 
disease progression over time upon ZF-R6 delivery at one month of age. 
Indeed up to three months after the treatment, in the control-treated eyes we 
recorded a 40% reduction of visual function compared to the baseline while in 
the study-group eyes, the drop was only 10%. 
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As a consequence, our findings extend the possible uses of artificial zinc finger-
based DNA binding proteins as a new paradigm in gene therapy to treat 
dominant diseases based on the modulation of an endogenous gene 
expression. 
The common therapeutic approach to date for the treatment of gain-of-function 
mutations mainly rely on RNAi-mediated downregulation of a gene-causing a 
disease. The first example of such therapeutic strategy in vivo was assessed to 
silence a dominant allele of ataxin-1 in order to treat a spinocerebellar ataxia 
type 1 (SCA1) in mutational independent manner and then applied to other 
mouse models of human disease including the P347S adRP mouse73; 74. Thus, 
based on the data presented here, either transcriptional (artificial ZFP 
technology) or post-transcriptional (RNAi) silencing strategies may be 
considered alternatives to one another; however, a side-by-side comparison is 
needed to determine which of the two systems is the safest and the most 
efficacious. In principle, ZFP technology has the advantage that the target 
sequences are present in one or two copies/diploid genome, whereas the 
mRNA transcripts (the RNAi targets) are highly abundant. It is worth 
emphasizing that rhodopsin is expressed extremely highly in the retina with 6.4 
million rod photoreceptor cells, each producing a steady-state level of 60 million 
of rhodopsin molecules (550–650 pmol)196. Moreover, besides the off-target 
silencing events which potentially set hurdles for the development of a safe 
ZFP- or RNAi-based system, studies have shown that high levels of siRNA may 
cause cellular toxicity through various mechanisms. Fatality in mice was 
associated with the downregulation of liver-derived microRNAs (miRNAs), 
indicating possible competition of the latter with shRNAs for limiting cellular 
factors required for the processing of various small RNAs197; 198. Also, an 
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attractive and therapeutic valuable feature of ZFPs is the possibility to control 
their expression levels through the use of inducible promoter systems which 
have not yet been optimized to control RNAi-based repression systems. 
Indeed, a key safety and efficacy element for the success of silencing strategies 
relies on fine-tuning control of the expression levels of the repressor system. In 
addition, a considerable potential advantage of ZF-mediated transcriptional 
control of an endogenous gene includes the ability to regulate all the natural 
splice variants of the target with a single therapeutic molecule. This of course is 
not the case of rhodopsin but it has already been demonstrated to be an 
important advantage in other therapeutic approaches181. Finally, the versatility 
of ZFPs design theoretically allows to switch the repressor with an activator 
domain (maintaining the same DBD) to treat also dominant diseases due to 
haploinsufficiency.  
Mutation-independent approaches such as the strategy exploited in this study 
for rhodopsin linked adRP, are extremely valuable technically and economically 
as a single therapeutic agent that may provide a remedy for many different 
mutant alleles of a disease gene (for example in the case of rhodopsin, more 
than 150 different mutations have been identified in its sequence). 
However, although this strategy may provide a rational solution for many 
dominant conditions, the application of the approach is complex. Indeed, one 
limitation of the mutational-independent silencing is the simultaneous 
repression of both the mutated and the normal alleles. As a consequence, a 
therapeutic strategy based on such approach must consider the development of 
a two-components system able to suppress both mutant and wild-type alleles of 
a target gene and simultaneously to provide a replacement gene that encodes 
wild-type protein but which is refractory to suppression. 
 76
 - Discussion - 
 77
The results presented here represent an in vivo demonstration that suppression 
through an artificial transcription factor and replacement given by the 
endogenous murine gene may provide benefit in an animal model of a 
dominant retinal disease. Thus, one future development will be to determine 
whether, in an amenable mouse model (ideally, harboring both a mutated and a 
normal allele of the human rhodopsin gene on a murine rhodopsin knock-out 
background), down-regulation of both alleles will be sufficient to inhibit/delay the 
disease progression or whether simultaneous replacement with a human 
rhodopsin transgene not sensitive to the treatment would be necessary. In the 
latter case, a vector incorporating both the artificial ZF-based repressor and the 
replacement gene ensuring their simultaneous expression will be required (for 
instance with bidirectional promoters enabling the coordinate expression of the 
two transgenes199). Moreover, it has been shown that either high or low 
rhodopsin expression levels can be deleterious to rod function, suggesting that 
tight regulation of rhodopsin expression levels is required for successful 
application of retinal repression-replacement strategy.  
Our data demonstrate that the novel and generally applicable mutational-
independent strategy based on artificial zinc finger proteins enables the 
transcriptional control of an endogenous causative gene and has perspectively 
therapeutic relevance for the treatment of diseases due to gain of function 
mutations. 
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